The Supreme Court held that combining a generic word with “.com” does not automatically make the resulting term generic; whether a term is generic depends on consumer perception, and “Booking.com” is not generic for hotel reservation services.
The Federal Circuit held that direct competitors have Article III standing to appeal an IPR final written decision even without a specific threat of patent infringement litigation, so long as their commercial activities risk infringement and the patent owner has refused to grant a covenant not to su
The Federal Circuit held that claim preclusion and the Kessler doctrine barred PersonalWeb from re-suing Amazon’s customers for infringement of the same patents, after PersonalWeb had previously settled a lawsuit against Amazon itself without expressly reserving its rights to sue downstream customer
The Federal Circuit addressed whether a standard-essential patent holder’s injunction request against a licensee who rejected a FRAND license offer was properly denied — examining the standards for determining whether a license offer was FRAND-compliant and whether refusal to accept a FRAND of
The Federal Circuit reversed a district court’s dismissal and held that patent claims covering a technique for reducing transmission delays in wireless communication systems were directed to a patent-eligible improvement in computer functionality rather than an abstract idea.
The Supreme Court held 5–4 that Georgia’s officially adopted annotated code — including annotations prepared under legislative supervision — is not copyrightable under the government edicts doctrine, because works created by government officials exercising legislative or judicial authority bel
The Federal Circuit affirmed that the USPTO’s subject matter eligibility guidance is not binding on the courts, and that the proper legal standard for patent eligibility remains the Alice/Mayo framework as interpreted by federal court precedent.
The Supreme Court held unanimously that a plaintiff in a trademark infringement case may recover the defendant’s profits under 15 U.S.C. §1117(a) without proving that the infringement was willful.
The Federal Circuit held that assignor estoppel bars a patent assignor from challenging claim validity in district court, but does not prevent the same assignor from filing inter partes review petitions at the PTAB — a critical distinction with major implications for post-grant strategy.
The Federal Circuit held that a patent term extension under the Hatch-Waxman Act covers only the active ingredient actually approved by the FDA—and its salts and esters—but does not extend to a metabolite of that ingredient, even if the metabolite is what is pharmacologically active in the body.